Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Cost Estimate Drops To $373 Bil. Over 10 Years

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS attributes the 41 percent drop from the original $634 billion estimate in part to better-than-anticipated drug price negotiations by Part D plans and a decline in drug cost trend.

You may also be interested in...



Part D Donut Hole Costs Drug Manufacturers $461 Million Through First Half Of 2011

The pace of those taking advantage of the 50% discount on brand drugs provided by manufacturers is accelerating as the year progresses, with 899,000 beneficiaries getting the discounts through the end of June.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel